Výsledky vyhľadávania

Nájdených záznamov: 321  
Váš dotaz: Autor-kód záznamu + druh.dok = "^sllk_un_auth 0012742 xcla^"

  1. 1.10 rokov občianskeho združenia Europacolon

    10 rokov občianskeho združenia Europacolon .  Onkológia. - ISSN 1336-8176 . - Roč. 12, č. 2 (2017), s. 94  
    C 3069
    článok

    článok

  2. 2.A case report of a patient with inoperable primary diffuse leptomeningeal melanomatosis treated with whole-brain radiotherapy and pembrolizumab

    A case report of a patient with inoperable primary diffuse leptomeningeal melanomatosis treated with whole-brain radiotherapy and pembrolizumab  / Palacka P. ... [et al.] .  Onkológia. - ISSN 1336-8176 . - Roč. 17, č. 1 (2022), s. 68  
    C 3069
    článok

    článok

  3. 3.A clinical predictive model of multidrug resistance in neutropenic cancer patients with bloodstream infection due to Pseudomonas aeruginosa (IRONIC study)

    A clinical predictive model of multidrug resistance in neutropenic cancer patients with bloodstream infection due to Pseudomonas aeruginosa (IRONIC study)  / Drgona L. ... [et al.] .  Onkológia. - ISSN 1336-8176 . - Roč. 15, č. 2 (2020), s. 148  
    C 3069
    článok

    článok

  4. 4.A disintegrin and metalloprotease 23 hypermethylation predicts decreased disease-free survival in low-risk breast cancer patients

    A disintegrin and metalloprotease 23 hypermethylation predicts decreased disease-free survival in low-risk breast cancer patients  / Karaba M. ... [et al.] .  Onkológia. - ISSN 1336-8176 . - Roč. 14, č. 2 (2019), s. 140  
    C 3069
    článok

    článok

  5. 5.A Phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim in patients receiving first-line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for locally advance or metastatic colorectal cancer: final results of the pegfilgrastim and anti-VEGF evaluation study (PAVES)

    A Phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim in patients receiving first-line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for locally advance or metastatic colorectal cancer: final results of the pegfilgrastim and anti-VEGF evaluation study (PAVES)  / Salek T. .  Onkológia. - ISSN 1336-8176 . - Roč. 12, č. 5 (2017), s. 379  
    C 3069
    článok

    článok

  6. 6.A system and a device for isolation circulating tumor cells from the peripheral blood in vivo

    A system and a device for isolation circulating tumor cells from the peripheral blood in vivo  / Michal Mego et al. .  Onkológia. - ISSN 1336-8176 . - Roč. 10, č. 5 (2015), s. 336  
    C 3069
    článok

    článok

  7. 7.ABVD or BEACOPPbaseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)–Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial

    ABVD or BEACOPPbaseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)–Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial  / Vranovsky A. ... [et al.] .  Onkológia. - ISSN 1336-8176 . - Roč. 12, č. 3 (2017), s. 222  
    C 3069
    článok

    článok

  8. 8.Access to novel drugs for non-small cell lung cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis

    Access to novel drugs for non-small cell lung cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis  / Berzinec P. ... [et al.] .  Onkológia. - ISSN 1336-8176 . - Roč. 15, č. 1 (2020), s. 67  
    C 3069
    článok

    článok

  9. 9.Access to novel drugs for non-small cell lung cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis

    Access to novel drugs for non-small cell lung cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis  / Berzinec P. ... [et al.] .  Onkológia. - ISSN 1336-8176 . - Roč. 15, č. 3 (2020), s. 226  
    C 3069
    článok

    článok

  10. 10.Activity and safety of crizotinib in patients with advanced clear cell sarcoma with MET alterations. European Organization for Research and Treatment of Cancer phase 2 trial 90101 "CREATE"

    Activity and safety of crizotinib in patients with advanced clear cell sarcoma with MET alterations. European Organization for Research and Treatment of Cancer phase 2 trial 90101 "CREATE"  / Sufliarsky J. .  Onkológia. - ISSN 1336-8176 . - Roč. 12, č. 5 (2017), s. 379  
    C 3069
    článok

    článok


  Tieto stránky využívajú súbory cookies, ktoré uľahčujú ich prezeranie. Ďalšie informácie o tom ako používame cookies.

Prijať všetkoNastavenieOdmietnuť všetko